<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557661</url>
  </required_header>
  <id_info>
    <org_study_id>NIL-CDNP-CT002</org_study_id>
    <nct_id>NCT00557661</nct_id>
  </id_info>
  <brief_title>Safety Study of CD-NP in Heart Failure</brief_title>
  <official_title>A Multi-Center, Ascending Dose Trial to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CD-NP Infusions in Patients With Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nile Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nile Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label study designed to determine the safety, tolerability and pharmacodynamics of&#xD;
      CD-NP infusions in heart failure patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of CD-NP infusions in patients with heart failure</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of CD-NP infusions on urinary flow rate, urinary sodium and potassium excretion</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Congestive Heart Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD-NP</intervention_name>
    <description>24 hr intravenous infusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Male or female â‰¥18 years of age diagnosed with NYHA class III or IV heart failure in&#xD;
             the last six months&#xD;
&#xD;
          -  Female patients must be post-menopausal or surgically sterile&#xD;
&#xD;
          -  Diagnosed heart failure with left ventricular ejection fraction &lt;40% obtained within&#xD;
             the prior 6 months with at least one symptoms or signs of volume overload&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, breast-feeding or of child-bearing potential&#xD;
&#xD;
          -  Clinically unstable patients&#xD;
&#xD;
          -  Major surgical procedures within 30 days of entry&#xD;
&#xD;
          -  Febrile temp &gt; 100 degrees F)&#xD;
&#xD;
          -  Symptomatic carotid disease, critical carotid stenosis, or stroke within 3 months&#xD;
             prior to study entry&#xD;
&#xD;
          -  Currently on IV vasoactive support (e.g., heart transplant candidate)&#xD;
&#xD;
          -  History of unexplained syncope within the past 3 months&#xD;
&#xD;
          -  History of organ transplantation&#xD;
&#xD;
          -  Comorbidities such as clinically significant cardiac valvular stenosis, aortic&#xD;
             valvular disease, restrictive cardiomyopathy, hypertrophic obstructive cardiomyopathy,&#xD;
             constrictive pericarditis, primary pulmonary hypertension, infiltrative disease,&#xD;
             uncorrected congenital heart disease, acute coronary syndrome, restrictive heart&#xD;
             failure, or any other condition which, in the opinion of the Investigator, would&#xD;
             prevent a patient's participation in the study.&#xD;
&#xD;
          -  Participation in a clinical trial of any investigational therapy or device within 30&#xD;
             days prior to randomization.&#xD;
&#xD;
          -  Treatment with nesiritide within 14 days prior to dosing.&#xD;
&#xD;
          -  Inability to effectively communicate with study personnel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Goldsmith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hennepin County Medical Center, Minneapolis</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>November 12, 2007</study_first_submitted>
  <study_first_submitted_qc>November 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <last_update_submitted>March 23, 2009</last_update_submitted>
  <last_update_submitted_qc>March 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2009</last_update_posted>
  <keyword>Heart failure</keyword>
  <keyword>CD-NP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

